Abbott Laboratories Corporation

Abbvie Inc.

Stanley DiDomenico

Richard J Perner

Arthur Gomtsyan

Erol K Bayburt

Robert G Schmidt

John R Koenig

Michael E Kort

Chih-hung Lee

Guo Zhu Zheng

Jun Chen

Sean Colm Turner

Anil Vasudevan

Irene I Drizin

Tammie K White

Philip R Kym

Andrew O Stewart

Jerome F Daanen

Eric A Voight

Ming Clinton Yeung

Xenia Beebe Searle

Daria Darczak

Heath A McDonald

Michael R Schrimpf

Michael J Rozema

Daniel P Larson

Arthur R Gomtsyan

Compounds of formula (I) wherein R, R, R, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPA1 antagonists

Compounds of formula (I) wherein R, R, R, m, and Y are defined in the specification are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L, L, R, R, and Rare as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) wherein R, R, R, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Z, and L are defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor

The isoquinoline compounds of formula (I)are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The 'R', 'Z' and &#x201c;L&#x201d; variables are defined in the disclosure and the &#x201c;X&#x201d; variables are defined as follows:

Compounds of formula (I)are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Growing community of inventors

Richmond, IL, United States of America

Stanley DiDomenico